IMXI's Approval Lasted Hours. WBD Just Cleared Every Regulator on Earth.
New York approved the Western Union/Intermex deal on August 13. California's DFPI suspension letter is dated the same day — August 13. Same-day approval and reopening bookends a week where two of the tracker's biggest names moved in opposite directions on regulatory certainty — while Warner Bros. Discovery quietly finished the cleanest possible sweep, satisfying every regulator in 68 countries with zero objections anywhere. In between: a routine-looking dig into Clear Channel's buyer consortium turned up a live federal fraud investigation, Caesars' months-long go-shop mystery finally got explained in a proxy filing, and we rebuilt the entire Risk/Reward ranking from scratch using an institutional, duration-adjusted framework that surfaced a pick nobody would have found on a spread screen.
80
Active Deals
1.55%
Median Spread
~$806B
Total Value
11
New This Week
This Week’s Top Moves
$IMXI9.7%
Same day: NYDFS approves, California reopens
Both letters are dated August 13, 2026. NYDFS approved the Western Union/Intermex deal that day — the last of 52 required US jurisdictions — and IMXI jumped roughly 35% after hours. The California Department of Financial Protection and Innovation's letter suspending a previously-granted approval extension from July 31 carries the identical date. Not a sequence of events over a bad week — the same calendar day produced both the deal's best news and its newest complication. DFPI cited a need to "further review the transaction as a result of the intervening six months since approval was originally granted." Not a new objection — a state that had already cleared this deal, reopening its own prior sign-off.
The spread settled back out to roughly 9.7%, wider than a deal-nearly-done level but far tighter than before NYDFS cleared. WU and Intermex say they're engaging with DFPI to seek reinstatement and remain committed to closing promptly once resolved. Our read: DFPI's stated rationale is about elapsed time and wanting a fresh look, not a specific objection to the deal's substance — this looks more like a process reopening than a new fight. WU also carries no contractual right to walk tied to state approvals, unlike some names in this tracker — a real distinction that keeps this at #2 in our Risk/Reward ranking despite the whiplash, rather than dropping further.
Paramount announced Friday that it has satisfied every regulatory clearance required under the merger agreement — an eight-month review spanning 68 jurisdictions worldwide, including the EU, UK, Australia, Canada, Brazil, China, the US Department of Justice, and finally Mexico. Zero blocks, anywhere. Paramount's own statement doesn't hide the frustration: the deal "could and would close today... but for the actions of just 12 state attorneys general."
That's the nuance worth sitting with. Antitrust risk on this deal is now genuinely zero — a real, total de-risking. But it doesn't change the binding constraint: the July 24 stipulation still keeps this closed until five days after a merits ruling or June 1, 2027, and trial remains set for March 2–19, 2027 regardless of how many regulators signed off. Paramount is now publicly pressuring the states to "engage in good faith," isolating them as the sole global holdout — a real negotiating escalation worth watching for any settlement signal, though nothing's confirmed yet.
The cleanest deal in the tracker has a very messy buyer
CCO screens about as well as anything we track: shareholder vote done, HSR done, CFIUS the only remaining condition. Digging into the buyer consortium for context turned up something the spread wasn't pricing at all. TWG Global — Mark Walter's holding company, the minority/operating partner alongside lead investor Mubadala — is under active SEC and DOJ investigation after Walter's insurers restated related-party loan exposure from $1.4B (3% of invested assets) to over $17 billion (39%), the highest such exposure among North American life insurers. Ratings agencies have moved to negative outlook. Walter's $12.5B Lakers sale is reported to be partly a liquidity move to help restructure the affiliated loans. The pointed question, per Bloomberg Law: whether Mubadala — the same entity leading the CCO consortium — was given accurate information when it invested $10B into TWG itself.
None of this touches CCO's own regulatory path directly, and CCO isn't a named target. But it's a real counterparty-quality overhang on one consortium partner, not a footnote. We're still comfortable with this as our top risk-adjusted pick this week — see below for why — but "clean" and "story-free" aren't the same thing.
The Icahn mystery, explained: he lost on structure, not price
A preliminary proxy filed August 12 finally revealed what happened during Caesars' go-shop: of 20 parties contacted, only Carl Icahn showed up, with a non-binding $34.00/share cash bid — three dollars above Fertitta's agreed $31.00. Higher headline price, and Caesars turned it down anyway. The reasons are the interesting part: Icahn's structure carried $6.5B in new debt from Jefferies (versus Fertitta's deal, which leaves most existing Caesars debt in place), an unsigned and incomplete financing commitment, and a rollover-equity ask the controlling Carano family declined once they saw the leverage and reduced free-cash-flow profile. CEO Tom Reeg was reportedly "lukewarm" on the terms from the start. No Superior Proposal resulted; the board's extended the deadline twice to be thorough, then stuck with Fertitta. Clean process, deal intact — and a good real-world reminder that headline price isn't the whole story in a competing-bid situation.
The clause names the affiliate directly — not a loose inference
Following up on last week's BRCD chatter, we went back through the actual Burdensome Condition definition in the merger agreement. It enumerates five specific triggers, and one names BRCD (Brighthouse Reinsurance Company of Delaware) directly: any non-de-minimis adverse change to BRCD's reinsurance operations or the company's statutory accounting practices itself qualifies as grounds Aquarian isn't required to accept. That's a close textual match to the trader chatter, not speculation dressed up as analysis. Widest spread among quality positions in the tracker this week.
The board just bought their own stock, days apart, in the open market
Chairman/CEO Peter Marrone and two directors purchased roughly C$3.24 million in AAUC shares this week: Marrone C$2.14M across two buys (Aug 7 and 10), director Daniel Racine ~C$997K (Aug 11), and director Dino Titaro ~C$100K (Aug 6). This is the same leadership team that walked away from the C$5.5B Zijin buyout and took a $295M strategic stake instead — insiders putting real money in with their own names attached, right after the deal they broke, is about as clean a confidence signal as this business produces.
The fundamentals keep compounding while the takeover offer just sits there
DDI reported Q2 after the close this week, and it was a clean beat: revenue $94.3M (+11.2% YoY), $0.66 EPS per ADS, adjusted EBITDA $39.3M (+17.2% YoY), and direct-to-consumer hit a record 52.4% of social casino revenue — up from 15.4% a year ago. Aggregate net cash now sits at $521M, roughly $10.52/ADS on its own, against DoubleU Games' still-pending non-binding $11.25/ADS proposal. The special committee is still reviewing; no new timeline given.
Stock closed at $12.92 Friday — meaning the market is paying almost entirely for the cash on the balance sheet and giving very little credit for a business that keeps growing double digits with expanding margins. Classic stub/event setup: you're effectively getting a compounding, profitable operating business nearly for free while waiting on a takeover decision that could land any quarter.
$ATKR — Atkore → Prysmian — $95.00 cash (~$3.8B) — Year-end 2026 $ITGR — Integer Holdings → KKR — $127.00 cash (~$5.7B) — Year-end 2026 $LNTH — Lantheus → Curium — $102.50 cash + CVR up to $12.00 (~$8.0B) — H1 2027 $BOW — Bowhead Specialty → American Family — $34.00 cash (~$1.2B) — Year-end 2026 $CHMI — Cherry Hill Mortgage → TPG Mortgage Trust (MITT) — $0.93 + 0.3063 MITT shares — Q4 2026 $VREX — Varex Imaging → Teledyne — $18.90 cash (~$1.1B) — Early 2027 $HZO — MarineMax → Safe Harbor Marinas (Blackstone) — $53.00 cash (~$1.5B) — Year-end 2026 $TYFG — Tri-County Financial → HBT Financial — election, cash/stock/mix, prorated — Early 2027 $DV — DoubleVerify → Nielsen (Elliott-backed) — $13.60 cash (~$2.15B) — Q1 2027 $BWMN — Bowman Consulting → Bernhard Capital Partners — $43.00 cash (~$1.0B) — Year-end 2026 $BZH — Beazer Homes → Dream Finders Homes — $33.50 cash (~$915M / $2.2B EV) — Year-end 2026 Two flagged for extra attention: $MKTX (added last week) carries real Second Request risk we don't think its ~2.6% spread fully prices — ICE agreed to a $327.4M regulatory termination fee, the kind of number only negotiated when both sides expect genuine antitrust exposure. And $LNTH follows the same CVR convention as $ATAI: we model the $102.50 cash-only component, not the contingent milestone value, so the headline spread understates total potential upside on purpose.
Binary Events on the Calendar
Aug 19 — $ZIM Q2 earnings. First real read on how much of the transpacific rate spike reaches the income statement — and the next data point on a deal that's now compressed from 42% to 24% in two weeks without a confirmed catalyst.
Aug 31 — $TWO close target (already "Approved" status — among the most advanced deals in the tracker).
Sept 6 — $BHF outside date (extendable to Dec 6 only in specified circumstances).
Sept 9 — Israel's government-bodies decision on $ZIM/Hapag-Lloyd — the date that likely confirms whether this deal lives or dies.
Sept 30 — $IMXI and $CCO close targets (IMXI contingent on DFPI reinstatement).
Top 6 by Spread — August 15, 2026
Ticker
Deal
Spread
Key Risk
$ZIM
Hapag-Lloyd / ZIM
24.3%
Israeli rejection expected per Aug 10 reporting; Hapag CEO publicly reaffirmed confidence Aug 13
$BHF
Aquarian / Brighthouse
19.3%
Burdensome Condition clause specifically names BRCD; real, not speculative
$NSC
Union Pacific / Norfolk Southern
14.4%
Prima facie denial motion live; annualizes to only ~16.5% given long timeline
$WBD
Paramount Skydance / WBD
10.75%
Regulatory risk now zero; litigation timeline (trial March 2027) unchanged
$IMXI
Western Union / Intermex
9.66%
NYDFS approved, California reopened same day — timeline itself now uncertain
$GSAT
Amazon / Globalstar
9.24%
HSR cleared; FCC docket clean aside from one meritless-looking objection
Top 6 by Risk-Adjusted Expected Return — Rebuilt August 15
#
Ticker
Why
Annualized
#1
$CCO
4.3% spread, ~6 weeks to close — annualizes to ~34% on one of the cleanest deal-specific risk profiles tracked (vote + HSR done, CFIUS only). Real counterparty overhang on TWG Global (see above), sized accordingly.
~34%
#2
$IMXI
~77% annualized if Sept 30 holds. WU has no contractual right to walk tied to state approvals (unlike BHF) and has repeatedly reaffirmed commitment; 51 of 52 US jurisdictions plus all international approvals are done. Real caveat: the timeline itself is in question until California's DFPI reinstates.
~77%*
#3
$BHF
Best raw return-per-unit-time (~62% annualized), but the risk is structurally different from IMXI's: the Burdensome Condition clause is a real, negotiated right for Aquarian to walk, and it specifically names BRCD. A documented buyer exit, not just a timing delay.
~62%
#4
$WBD
Modest ~18% annualized, but risk is now unusually well-bounded: regulatory risk hit zero this week, one dated variable (March 2027 trial) remains.
~18%
#5
$GSAT
The "sleep well at night" pick. Lowest identified tail risk in the group, traded off against a long mid-2027 timeline (~11% annualized).
~11%
#6
$NSC
The marginal pick. Headline 14.4% spread annualizes to just ~16.5% once the long timeline is priced in, and real opposition is live — included only because every longer-dated alternative annualizes lower still.
~16.5%
Methodology note: this ranking now explicitly weighs duration (annualized return, not headline spread) and downside severity, not just spread size — a genuinely different lens than a pure spread screen. $ZIM excluded on purpose despite the widest spread in the tracker: real government-veto binary risk has no place in a top tier built to avoid permanent capital loss. $IRDM dropped out despite high certainty — its long mid-2027 close produced the weakest annualized return of everything considered. *IMXI's 77% assumes the Sept 30 date holds; treat it as a best-case, not a base-case number this week.
Deals Removed This Week
$TMHC — Taylor Morrison × Berkshire Hathaway — $72.50 cash — CLOSED July 24 $MDV — Modiv Industrial × Global Net Lease — 1.975 GNL shares — CLOSED August 12 $ADW.A — Andrew Peller × Fairfax Financial — $8.00/$12.00 cash — CLOSED August 14 $DHIL — Diamond Hill × First Eagle Investments — $175.00 cash — CLOSED April 22
If you find ArbLens useful, consider sharing it with at least one person who might benefit — a fellow investor, analyst, or anyone who follows M&A. It’s free, and word of mouth is how this community grows. arblens.com
Real-time deal alerts, spread movements, and analysis as they happen — follow @ArbLens between issues.
Get weekly merger arb insights delivered to your inbox — spreads, regulatory updates, and what to watch next.
For informational purposes only. Nothing here constitutes investment advice. Merger arbitrage involves significant risk including deal failure and loss of capital. Data sourced from public filings and third-party sources. Spreads shown are as of August 15, 2026 and update nightly on arblens.com.